摘要
Данная статья является продолжением публикации, посвященной особым типам рака молочной железы (РМЖ), история изучения которого насчитывает тысячелетия. Современная онкология рассматривает РМЖ как гетерогенную группу заболеваний, различающихся по морфологии, молекулярным подтипам и клиническому течению. Благодаря развитию диагностики и персонализированной терапии, смертность от РМЖ существенно ниже, чем при других агрессивных опухолях, таких как рак поджелудочной железы или печени.
Во второй части публикации речь пойдет о редких и особых гистологических типах РМЖ с неблагоприятным и неясным прогнозом. Классификация этих форм основывается не только на морфологических, но и на иммуногистохимических, молекулярных и прогностических характеристиках, что отражает современный клинический подход.
В исследовании, проведенном на базе НМИЦ онкологии им. Н.Н. Петрова, частота особых типов РМЖ (без учета дольковых карцином) составила 8,12 % всех случаев, а наиболее часто встречались муцинозный и папиллярный типы, которые чаще характеризуются благоприятным прогнозом. Вместе с тем такие формы, как метапластический, нейроэндокринный и микропапиллярный рак ассоциированы с худшими исходами и составляют около трети всех особых форм.
Данные НМИЦ онкологии им. Н.Н. Петрова (Санкт-Петербург) сопоставимы с результатами анализа, представленного Научно-исследовательской онкологической клиникой при университетской клинике Анкары (Ankara Oncology Training and Research Hospital of the University of Health Sciences), что подтверждает универсальность выявленных закономерностей. Особые типы с благоприятным прогнозом, но трижды негативным фенотипом (например, аденокистозный, ацинарноклеточный, секреторный рак) требуют дальнейшего изучения из-за их редкости и потенциальной клинической значимости.
В заключении подчеркивается, что клиническое поведение особых форм РМЖ не всегда соответствует их биологическим особенностям, что затрудняет прогнозирование. Выбор терапии должен базироваться на комплексной оценке морфологических, иммуногистохимических и молекулярных характеристик опухоли, а также клинических данных. Персонализированный подход к лечению особых типов РМЖ становится ключевым фактором для улучшения исходов у данной категории пациентов.
参考
Lukong K.E. Understanding breast cancer – The long and winding road. BBA Clinical. 2017: 7.
WHO classification of tumours. Breast Tumours. International Agency for Research on Cancer. 2019; 356.
Jenkins S., et al. Rare breast cancer subtypes. Current Oncology Reports. Springer. 2021; 23(5).
Al-Baimani K., et al. Invasive pleomorphic lobular carcinoma of the breast: Pathologic, clinical, and therapeutic considerations. Clinical Breast Cancer. 2015; 15(6).
Hoda S.A.F., et al. Rosen’s breast pathology. 5th edition. Philadelphia: Wolters Kluwer. 2021; 1.
Butler D., Rosa M. Pleomorphic lobular carcinoma of the breast: a morphologically and clinically distinct variant of lobular carcinoma. Archives of Pathology & Laboratory Medicine. 2013; 137(11).
Weigelt B., et al. The molecular underpinning of lobular histological growth pattern: a genome — wide transcriptomic analysis of invasive lobular carcinomas and grade‐ and molecular subtype — matched invasive ductal carcinomas of no special type. The Journal of Pathology. 2010; 220 (1): 45–57.
Tan P.H., et al. Histiocytoid breast carcinoma: an enigmatic lobular entity. J Clin Pathol. 2011; 64 (8): 654–659.
Sanli A.N., Kara H., Tekcan Sanli D.E., et al. Comparison of clinicopathologic features and survival outcomes of pleomorphic lobular, classical lobular, and invasive ductal carcinoma. World J Surg. 2025; 49 (6): 1406–1417.-DOI: 10.1002/wjs.12589.
Bell C. A system of operative surgery : founded on the basis of anatomy. Longman, Hurst, Rees, and Orme. London: Francis A. Countway Library of Medicine. 1807; 1.
Lee B.J., Tannenbaum E. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of the Memorial Hospital. Surg Gynecol Obstet. 1924; 39: 580–595.
Dawood S., et al. International expert panel on inflammatory breast cancer: Consensus statement for standardized diagnosis and treatment. Annals of Oncology. 2011: 22(3).
Amin M.B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population — based to a more “personalized” approach to cancer staging. CA: A Cancer Journal for Clinicians. Wiley. 2017; 67 (2): 93–99.
Tschen E.H., Apisarnthanarax P. Inflammatory metastatic carcinoma of the breast. Arch Dermatol. 1981; 117(2): 120-121.
Wu S.G., et al. Inflammatory breast cancer outcomes by breast cancer subtype:A population-based study. Future Oncology. 2019; 15 (5).
Anderson W.F., Schairer C., Chen B.E., et al. Epidemiology of inflammatory breast cancer (IBC). Breast disease. 2005; 22: 9–23.-DOI: 10.3233/bd-2006-22103.
Dawood S., Ueno N.T., Valero V., et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 2011; 117 (9): 1819–1826.-DOI: 10.1002/cncr.25682.
Fisher E.R., et al. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 1975; 36 (1): 1–85.
Kaufman M.W., et al. Carcinoma of the breast with pseudosarcomatous metaplasia. Cancer. 1984; 53 (9): 1908–1917.
Pezzi C.M., et al. Characteristics and treatment of metaplastic breast cancer: Analysis of 892 cases from the national cancer data base. Annals of Surgical Oncology. 2007; 14 (1).
Vranic U., Swensen S., Feldman J., et al. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. Journal of Clinical Pathology. 2017; 70 (3): 255-259.-DOI: 10.1136/jclinpath-2016-203874.
Bae S.Y., et al. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Research and Treatment. 2011; 126 (2).
Al-Hilli Z., Choong G., Keeney M.G., et al. Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. Breast Cancer Research and Treatment. 2019; 176 (3): 709-716.-DOI: 10.1007/s10549-019-05264-2.
Adams S., Othus M., Patel S.P., et al. A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART, SWOG S1609). Clinical Cancer Research: an official journal of the American Association for Cancer Research. 2022; 28 (2): 271–278.-DOI: 10.1158/1078-0432.CCR-21-2182.
Tsang J.Y., Tse G.M. Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification. Mod Pathol. 2021; 34 (6): 1062–1073.-DOI: 10.1038/s41379-021-00736-7.
Wang J., et al. Invasive neuroendocrine carcinoma of the breast: A population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer. 2014; 14 (1).
Кудайбергенова А.Г., et al. Современные представления о нейроэндокринных опухолях/карциномах молочной железы. Онкопатология. 2018. Т. 1, № 2. [Kudaibergenova A.G., et al. Current views on neuroendocrine tumors/carcinomas of the breast. Oncopathology. 2018; 1 (2) (In Rus)].
Lavigne M., et al. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Modern Pathology. 2018; 31 (1).
Wang J., et al. Invasive neuroendocrine carcinoma of the breast: A population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer. 2014; 14: 1.
Frame M.T., Gohal J., Mader K., Goodman J. Primary small cell carcinoma of the breast: an approach to medical and surgical management. Cureus. 2023; 15 (10): e47981.-DOI: 10.7759/cureus.47981.
Rakha E.A., et al. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. European Journal of Cancer. 2009; 45: 10.
Pareja F., Selenica P., Brown D.N., et al. Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma. Histopathology. 2019; 75 (1): 139-145.-DOI: 10.1111/his.13853.
Verras G.I., Tchabashvili L., Mulita F., et al. Micropapillary breast carcinoma: from molecular pathogenesis to prognosis. Breast Cancer (Dove Medical Press). 2022; 14: 41-61.-DOI: 10.2147/BCTT.S346301.
Marchiò C., et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. Journal of Pathology. 2008; 215 (4).
Qiu P., Cui Q., Huang S., et al. An overview of invasive micropapillary carcinoma of the breast: past, present, and future. Frontiers in Oncology. 2024; 14: 1435421.-DOI: 10.3389/fonc.2024.1435421.
Yun S.U., et al. Imaging findings of invasive micropapillary carcinoma of the breast. Journal of Breast Cancer. 2012; 15 (1).
Verras G.I., Tchabashvili L., Mulita F., et al. Micropapillary breast carcinoma: from molecular pathogenesis to prognosis. Breast Cancer (Dove Medical Press). 2022; 14: 41–61.-DOI: 10.2147/BCTT.S346301.
Aboumrad M.H., Horn R.C., Fine G. Lipid — secreting mammary carcinoma. Report of a case associated with paget's disease of the nipple. Cancer. 1963; 16 (4).
Ramos C.V., Taylor H.B. Lipid-rich carcinoma of the breast. A clinicopathologic analysis of 13 examples. Cancer. 1974; 33 (3): 812–819.
Zhang M., Pu D., Shi G., Li J. The clinical and pathological characteristics of lipid-rich carcinoma of the breast: an analysis of 98 published patients. BMC Women's Health. 2023; 23 (1): 301.-DOI: 10.1186/s12905-023-02449-2.
Balik E., Taneli C., Cetinkursun S., et al. Lipid secreting breast carcinoma in childhood: a case report. Eur J Pediatr Surg. 1993; 3 (1): 48-49.-DOI: 10.1055/s-2008-1063508.
Moritani S., et al. Intracytoplasmic lipid accumulation in apocrine carcinoma of the breast evaluated with adipophilin immunoreactivity: a possible link between apocrine carcinoma and lipid-rich carcinoma. Am J Surg Pathol. 2011; 35 (6): 861–867.
Ragazzi M., et al. Oncocytic carcinoma of the breast: Frequency, morphology and follow-up. Human Pathology. 2011: 42 (2).
Marucci G., Betts C.M., Frank G., Foschini M.P. Oncocytic meningioma: report of a case with progression after radiosurgery. Int J Surg Pathol. 2007; 15 (1): 77-81.-DOI: 10.1177/1066896906295824.
Lukovic J., Petrovic I., Liu Z., et al. Oncocytic papillary thyroid carcinoma and oncocytic poorly differentiated thyroid carcinoma: clinical features, uptake, and response to radioactive iodine therapy, and outcome. Front Endocrinol (Lausanne). 2021; 12: 795184.-DOI: 10.3389/fendo.2021.795184.
Alvarez Moreno J.C., He J. Invasive breast carcinoma with sebaceous morphologic pattern showing lymph node macrometastasis: a case report. Cureus. 2023; 15(4): e37365.-DOI: 10.7759/cureus.37365.
Cohen L.N., Flanagan C., Kong A.L., Cortina C.S. A systematic review of sebaceous carcinoma of the breast from 2000–2023: A rare entity with high recurrence rates. Surgical Oncology Insight. 2024; 1 (3): 100074.-DOI: 10.1016/j.soi.2024.100074.
de Alencar N.N., de Souza D.A., Lourenço A.A., da Silva R.R. Sebaceous breast carcinoma. Autopsy & Case Reports. 2022; 12: e2021365.-DOI: 10.4322/acr.2021.365.
Maia T., Amendoeira I. Breast sebaceous carcinoma — a rare entity. Clinico-pathological description of two cases and brief review. Virchows Archiv. 2018; 472 (5).
van Bogaert L.J., Maldague P. Histologic variants of lipid-secreting carcinoma of the breast. Virchows Archiv A Pathological Anatomy and Histology. 1977; 375 (4).
Zhou Z., et al. Clinical features, survival and prognostic factors of glycogen-rich clear cell carcinoma (GRCC) of the breast in the U.S. population. Journal of Clinical Medicine. 2019; 8 (2).
Eun N.L., et al. Clinical imaging of glycogen-rich clear cell carcinoma of the breast: A case series with literature review. Magnetic Resonance in Medical Sciences. 2019; 18 (3).
Singh G. R., Kumari M., Sunny K., et al. Interesting breast tumours: a tripod of cases. Nigerian Medical Journal: Journal of the Nigeria Medical Association. 2022; 65 (2): 222-230.-DOI: 10.60787/nmj-v65i2-312.
Zheng Y., Tang H., Liu Q., et al. Mutational analysis and protein expression of PI3K/AKT pathway in four mucinous cystadenocarcinoma of the breast. Diagnostic Pathology. 2025; 20 (1): 68.-DOI: 10.1186/s13000-025-01650-1.
Petersson F., et al. Mucinous cystadenocarcinoma of the breast with amplification of the HER2-gene confirmed by FISH: The first case reported. Human Pathology. 2010; 41 (6).
Sağdıç M.F., Özaslan C. Rare histological types of breast cancer: a single-center experience. Breast J. 2025; 9.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2025
